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becomes the dominant strategy after 2.5 years due to its lower
long-term cost of care. The average cumulative one and ﬁve-year
costs are $10,855 and $12,866 for ablation compared to $5163
and $24,377 for cardioversion and drug therapy. Over a 5-year
time horizon, the cumulative QALY gain with catheter ablation
is 0.64 at a cost-savings of greater than $11,500. CONCLU-
SION: For ﬁrst-line treatment of typical isthmus-dependent 
AFL, catheter ablation is more effective and less costly than 
cardioversion and drug therapy.
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OBJECTIVES: The objective of this study was to estimate the
existing ﬁnancial costs from obesity in the United Kingdom (UK).
METHODS: This comprehensive study was undertaken using a
number of data sources that included a measure of height and
weight. Population data were taken from published UK govern-
mental sources. NHS hospital utilisation data from a region, in
addition to corresponding specialized survey data (Health out-
comes data repository [HODaR]). Cost data were taken from
statistical governmental series and published sources (HRGs).
Estimates of ﬁnancial cost—including direct, indirect and intan-
gible costs—were available from HODaR. All costs for all
disease categories were calculated for different groups deﬁned by
age, sex and body mass index (BMI). Resulting values in alter-
native categories were compared using the Mann-Whitney U test,
comparing overweight and obese patients with ‘normal’ groups.
Provided the test indicated a signiﬁcant difference to the normal
group, the amount of additional costs was calculated and termed
excess costs. Prices are in UK£, 2002. Unusually, this considered
all diseases including those where obesity provides a protective
affect e.g., osteoporosis. RESULTS: In UK in 2002 approxi-
mately 10.5 million adults age >18 years were obese (BMI 
>30kg/m2), equivalent to 22.9% of the population. Total direct
excess costs were estimated as £1.5 billion. Proportionally, the
most costly excess cost category occurred in the provision of
social services. The indirect costs due to work loss in the 18–54
year-old group accounted for £2.7 billion. The marginal excess
costs accounted for 2.3% of the total NHS budget. Furthermore,
quality of life was signiﬁcantly lower in obese people. CON-
CLUSIONS: These results conﬁrm the current heavy ﬁnancial
toll of obesity in the UK. Obesity is already a major health
problem in the UK and if recent trends of increasing BMI con-
tinue it will intensify.
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OBJECTIVES: To compare the economic consequences of treat-
ment with either thiazolidinediones (TZD) or insulin in patients
with type-2 diabetes. METHODS: Type-2 diabetes patients ini-
tiating TZD or insulin treatment during the three-year period
(1999–2001) were identiﬁed from a Medicaid claims database.
The ﬁrst prescription for a TZD or insulin was treated as an
index prescription and health care costs in the 12-month follow-
up period were assessed. Analysis was restricted to a compliant
sample receiving at least six prescriptions of either TZD or
insulin. Propensity matching techniques were used to control for
selection bias and potential imbalances between the two treat-
ment groups. Semi-logarithmic OLS models were used to esti-
mate the impact of therapy on total and diabetes related health
care costs. The costs were also examined separately in terms of
Emergency Room (ER)/hospitalization, outpatient and prescrip-
tion costs using appropriate two-part models. Smearing esti-
mates were used to interpret the results from the semi-log
models. RESULTS: The propensity-matched sample consisted of
327 patients per treatment group with comparable demographic
and utilization parameters at baseline. In the 12-month follow-
up period, the TZD group incurred signiﬁcantly lower total
health care costs (19.1%; $10,606 vs. $13,062), ER/hospitaliza-
tion costs (58.2%; $2432 vs. $5826) and outpatient costs
(33.9%; $2672 vs. $4014) compared to the insulin group. The
TZD group also had signiﬁcantly lower diabetes related health
care costs (15.0%; $4877 vs. $5721), diabetes related ER/hos-
pitalization costs (69.1%; $1733 vs. $5613) and outpatient costs
(39.8%; $722 vs. $967) than the insulin group. The TZD group
had signiﬁcantly higher total (14.9%; $4687 vs. $4072) and dia-
betes related (63.0%; $1353 vs. $772) prescription costs. CON-
CLUSION: The results of the study suggest that despite its higher
acquisition cost, treatment with TZD signiﬁcantly reduces total
and diabetes-related health care costs as compared to insulin
therapy in patients with type-2 diabetes.
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OBJECTIVE: To determine the cost-effectiveness [CE] of non-
invasive myocardial perfusion imaging [MPI] in asymptomatic
individuals with diabetes mellitus [DM] for detection of CAD.
METHODS: A decision tree analysis using TreeAgeTM software
was completed to determine the probabilistic CE of MPI in com-
parison to stress echocardiography [ECHO] and do-nothing
management [DNM]. Probabilities for the analysis included
cardiac event incidence such as non-fatal MI and cardiac death
and percent of test results reported as abnormal/positive or
normal/negative for each diagnostic technique. Utilities consisted
of PPV and NPV values obtained from the published literature;
preference scores [zero to one scale] assigned to disease states
were similarly obtained. Medicare charges for 2004 were used
as surrogates of cost; mean charges for initial clinical assessment
[labs, etc.], exercise treadmill testing, ECHO, and MPI were all
included in the CEA. RESULTS: MPI demonstrated PPV of
92.9% in detecting CAD in asymptomatic patients with DM
compared to a stress ECHO PPV of 80%. However, ECHO is
the dominant strategy with a mean cost of $701 and effective-
ness ratio of 0.51. MPI demonstrated a mean cost of $1084 
with an effectiveness ratio of 0.60. The resulting ICER is
$4324/QALY. Importantly, DNM is dominated by MPI [p <
0.006] CONCLUSIONS: MPI is more effective and more costly
than stress ECHO but meets generally-regarded WTP thresholds
in asymptomatic individuals with DM. Use of diagnostic data
from MPI may impact clinical outcomes such as cardiac events
by inﬂuencing early management decisions.
